Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
Inventors
Wang, Guoqiang • Or, Yat Sun • Shen, Ruichao • Xing, Xuechao • Long, Jiang • Dai, Peng • Granger, Brett • He, Jing
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof,The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
Core Innovation
The claimed invention is a compound represented by Formula (III-10), or a pharmaceutically acceptable salt thereof, characterized by a polyhydroxylated fused-ring steroidal core. The chemical structure fixes R2 and Rc as hydrogen, m as zero, and R7 as ethyl, while R1 is selected from halogen, hydroxyl, substituted or unsubstituted C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, aryl, arylalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, and —NR10R11. Substituents R10 and R11 are independently hydrogen, alkyl, alkenyl, alkynyl, or cycloalkyl groups, or form a heterocyclic ring.
The description identifies bile-acid-derived compounds, including sulfonylurea, carbamate, and sulfonyl-carbamate analogs, that modulate FXR and TGR5 as selective or dual agonists. Representative steroidal compounds and sulfonamide building blocks bear varied aryl, cycloalkyl, and heteroaryl substituents, accompanied by in vitro FXR reporter-assay screening results and a TGR5 cAMP assay. Because the background section is not included in the supplied content, the problem being solved is not explicitly described in patent.
Claims Coverage
The supplied claim information identifies one independent claim and three inventive features across the independent claim and described dependent claims.
Formula (III-10) compound genus
Claim 1 covers a compound represented by Formula (III-10), or a pharmaceutically acceptable salt thereof, wherein R2 and Rc are hydrogen, m is 0, R7 is ethyl, and R1 is selected from halogen, hydroxyl, substituted or unsubstituted C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, aryl, arylalkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, or —NR10R11, wherein R10 and R11 are independently hydrogen or specified hydrocarbon groups, or form a heterocyclic ring.
Pharmaceutical composition
A dependent claim covers a pharmaceutical composition comprising the compound of Formula (III-10) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
Treatment of liver conditions
A dependent claim covers the treatment of nonalcoholic fatty liver disease or nonalcoholic steatohepatitis by administering a therapeutically effective amount of the compound of Formula (III-10) or a pharmaceutically acceptable salt thereof.
The claims cover the Formula (III-10) compound genus and, in described dependent claims, a pharmaceutical composition containing the compound and its therapeutic administration for specified liver conditions.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Treatment or prevention of FXR- or TGR5-mediated conditions, including metabolic, gastrointestinal, renal, cardiovascular, inflammatory, autoimmune, and cancer indications.
Treatment of liver diseases, specifically nonalcoholic fatty liver disease or nonalcoholic steatohepatitis, by administering a therapeutically effective amount of the claimed compound or pharmaceutical composition.
A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or excipient.
Interested in licensing this patent?